Interleukin-18 and coronary artery lesions in patients with Kawasaki disease

Journal of the Chinese Medical Association

Volumn 76, Issue 8, 2013, Pages 438-445

  Weng, Ken Pen ^a,b,c   Hsieh, Kai Sheng ^a   Huang, Shih Hui ^d   Ou, Shan F ^e   Lai, Tsung Jen ^a   Tang, Chia Wan ^a   Lin, Chu Chuan ^a   Ho, Tsyr Yuh ^e   Liou, Huei Han ^a   Ger, Luo Ping ^a,f  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Shu Zen College of Medicine and Management   (Taiwan)

^d FOOYIN UNIVERSITY   (Taiwan)

^e ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Coronary artery lesions; Interleukin 18; Kawasaki disease

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; IMMUNOGLOBULIN; INTERLEUKIN 18;

ARTERY LESION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PROSPECTIVE STUDY; VIRUS INFECTION;

CORONARY ARTERY LESIONS; INTERLEUKIN-18; KAWASAKI DISEASE;

C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; INTERFERON-GAMMA; INTERLEUKIN-18; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROSPECTIVE STUDIES;

EID: 84880952664     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2013.04.005     Document Type: Article

References (42)

1. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004, 110:2747-2771.
2. Suzuki A., Kamiya T., Kuwahara N., Ono Y., Kohata T., Takahashi O., et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986, 7:3-9.
3. Hsieh K.S., Weng K.P., Lin C.C., Huang T.C., Lee C.L., Huang S.M. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004, 114:e689-e693.
4. Juan C.C., Hwang B., Lee P.C., Lin Y.J., Chien J.C., Lee H.Y., et al. The clinical manifestations and risk factors of a delayed diagnosis of Kawasaki disease. J Chin Med Assoc 2007, 70:374-379.
5. Weng K.P., Ou S.F., Lin C.C., Hsieh K.S. Recent advances in the treatment of Kawasaki disease. J Chin Med Assoc 2011, 74:481-484.
6. Furukawa S., Matsubara T., Jujoh K., Yone K., Sugawara T., Sasai K., et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 1988, 48:247-251.
7. Suzuki H., Noda E., Miyawaki M., Takeuchi T., Uemura S., Koike M. Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatr Int 2001, 43:115-119.
8. Maury C.P., Salo E., Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 1988, 319:1670-1671.
9. Matsubara T., Furukawa S., Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990, 56:29-36.
10. Lin C.Y., Lin C.C., Hwang B., Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr 1992, 121:924-926.
11. Kim D.S., Lee H.K., Noh G.W., Lee S.I., Lee K.Y. Increased serum interleukin-10 level in Kawasaki disease. Yonsei Med J 1996, 37:125-130.
12. Hirao J., Hibi S., Andoh T., Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 1997, 112:152-156.
13. Nomura Y., Masuda K., Maeno N., Yoshinaga M., Kawano Y. Serum levels of interleukin-18 are elevated in the subacute phase of Kawasaki syndrome. Int Arch Allergy Immunol 2004, 135:161-165.
14. Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J Leukoc Biol 2003, 73:213-224.
15. Nakahira M., Ahn H.J., Park W.R., Gao P., Tomura M., Park C.S., et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002, 168:1146-1153.
16. Dinarello C.A. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999, 103:11-24.
17. + human blood mononuclear cells. J Clin Invest 1998, 101:711-721.
18. Gracie J.A., Forsey R.J., Chan W.L., Gilmour A., Leung B.P., Greer M.R., et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999, 104:1393-1401.
19. Pietrzak A., Janowski K., Chodorowska G., Michalak-Stoma A., Roliński J., Zalewska A., et al. Plasma interleukin-18 and dendritic cells in males with psoriasis vulgaris. Mediators Inflamm 2007, 2007:61254.
20. Chattergoon M.A., Levine J.S., Latanich R., Osburn W.O., Thomas D.L., Cox A.L. High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis 2011, 204:1730-1740.
21. Blankenberg S., Tiret L., Bickel C., Peetz D., Cambien F., Meyer J., et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106:24-30.
22. Jefferis B.J., Papacosta O., Owen C.G., Wannamethee S.G., Humphries S.E., Woodward M., et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis 2011, 217:227-233.
23. Chen S.Y., Wan L., Huang Y.C., Sheu J.J., Lan Y.C., Lai C.H., et al. Interleukin-18 gene 105A/C genetic polymorphism is associated with the susceptibility of Kawasaki disease. J Clin Lab Anal 2009, 23:71-76.
24. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease 1984, Japan Kawasaki Disease Research Committee, Ministry of Health and Welfare, Tokyo.
25. - cells during acute Kawasaki disease. Int Arch Allergy Immunol 2000, 22:293-298.
26. Kenis G., Teunissen C., De Jongh R., Bosmans E., Steinbusch H., Maes M. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine 2002, 19:228-235.
27. Ito Y., Nakachi K., Imai K., Hashimoto S., Watanabe Y., Inaba Y., et al. Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulin-like growth factor binding protein-3, transforming growth factor beta, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol 2005, 15:S67-S73.
28. Whitman S.C., Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002, 90:E34-E38.
29. Mallat Z., Corbaz A., Scoazec A., Graber P., Alouani S., Esposito B., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001, 89:E41-E45.
30. Anguera I., Miranda-Guardiola F., Bosch X., Filella X., Sitges M., Marín J.L., et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002, 144:811-817.
31. Weng K.P., Hsieh K.S., Hwang Y.T., Huang S.H., Lai T.J., Yuh Y.S., et al. IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. Circ J 2010, 74:983-989.
32. Peng Q., Wu Q., Chen C.H., Hong H., Zhang L.Y. Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi 2006, 8:208-210. [Article in Chinese].
33. Fukunishi M., Kikkawa M., Hamana K., Onodera T., Matsuzaki K., Matsumoto Y., et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000, 137:172-176.
34. Kobayashi T., Inoue Y., Takeuchi K., Okada Y., Tamura K., Tomomasa T., et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006, 113:2606-2612.
35. Sano T., Kurotobi S., Matsuzaki K., Yamamoto T., Maki I., Miki K., et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007, 166:131-137.
36. Egami K., Muta H., Ishii M., Suda K., Sugahara Y., Iemura M., et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006, 149:237-240.
37. Tremoulet A.H., Best B.M., Song S., Wang S., Corinaldesi E., Eichenfield J.R., et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008, 153:117-121.
38. Latino G.A., Manlhiot C., Yeung R.S., Chahal N., McCrindle B.W. Macrophage activation syndrome in the acute phase of Kawasaki disease. JPediatr Hematol Oncol 2010, 32:527-531.
39. Comenzo R.L., Malachowski M.E., Meissner H.C., Fulton D.R., Berkman E.M. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992, 120:926-928.
40. Furmanski P., Johnson C.S. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its invivo action as tumor necrosis factor. Blood 1990, 75:2328-2334.
41. Ogura T., Ueda H., Hosohara K., Tsuji R., Nagata Y., Kashiwamura S., et al. Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood 2001, 98:2101-2107.
42. Hayashi N., Matsui K., Tsutsui H., Osada Y., Mohamed R.T., Nakano H., et al. Kupffer cells from Schistosoma mansoni-infected mice participate in the prompt type 2 differentiation of hepatic T cells in response to worm antigens. J Immunol 1999, 63:6702-6711.